Dynavax Technologies Corp.
Immuno-focused company reports Q1 revenue of $12.7 million
Published in FDA Law Weekly, May 26th, 2005
Revenue for the first quarter ended March 31, 2005, was $12.7 million compared to $3.2 million for the same period in 2004. In March 2005, Dynavax and UCB Farchim (UCB) ended their allergy collaboration and Dynavax regained full rights to its allergy program.
Collaboration revenue for the first quarter 2005 reflects the ending of the UCB agreement and associated contractual terms. Included in first quarter 2005 collaboration revenue was a one-time noncash amount of $7 million resulting from the accelerated recognition of an upfront payment the company received...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
Source: FDA Law Weekly (2005-05-26)
More Articles from FDA Law Weekly
- AMTSystems
Identification device for surgical safety introduced in healthcare industry - Adeza
Test assesses risk of preterm birth - Adventrx Pharmaceuticals, Inc.
U.S. FDA grants clearance for CoFactor phase III trial in colorectal cancer - Alcon, Inc.
New intraocular lens launched - BioAlliance Pharma
U.S. FDA grants orphan drug designation for doxorubicin Transdrug - Cellegy Pharmaceuticals, Inc.
Pharmaceutical firm responds to U.S. FDA inquiries about Cellegesic - More from this issue of FDA Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
